Icon PLC (ICLR) Up 2.3% Since Last Earnings Report: Can It Continue?
Those Who Invested in ICON (NASDAQ:ICLR) Five Years Ago Are up 110%
$100 Invested In Icon 5 Years Ago Would Be Worth This Much Today
Executive Reshuffles: The ODP, GrafTech International and ICON Companies in Focus
Medicare's Negotiated Drug Prices Will Save Taxpayers $6 Billion in First Year, White House Says
US Drug Price Measure to Cut Costs by US$7.5b in 2026
Evercore Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $360
Truist Financial Maintains Icon PLC(ICLR.US) With Buy Rating
Icon Names Nigel Clerkin as Its New Chief Fincl Officer >ICLR
Express News | ICON PLC - Appoints Nigel Clerkin as New CFO
Express News | ICON Announces Appointment of New Chief Financial Officer
Investors in ICON (NASDAQ:ICLR) Have Seen Favorable Returns of 98% Over the Past Five Years
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Here's How Much You Would Have Made Owning Icon Stock In The Last 10 Years
Icon PLC (ICLR) Maintains Buy Rating: A Strong Financial Outlook Despite Industry Challenges
Express News | ICON PLC : Mizuho Raises Target Price to $370 From $360
Form 144 | Icon PLC(ICLR.US) Officer Proposes to Sell 8.5 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 29, $Icon PLC(ICLR.US)$ Officer BRENDAN BRENNAN intends to sell 26,064 shares of its common stock on Jul 29, with a total market value of approximately $8.5 million.
Market Participants Recognise ICON Public Limited Company's (NASDAQ:ICLR) Earnings
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $350 to $376
Icon Price Target Cut to $350.00/Share From $355.00 by Barclays